期刊
HAEMATOLOGICA
卷 92, 期 8, 页码 1149-1150出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.11228
关键词
cyclophosphamide; velcade and dexamethasone (CVD); comparable toxicity; high response rates
类别
The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据